Skip to content

The safety and effectiveness of early administration of tirofiban in patients treated with alteplase for acute ischemic stroke

The safety and effectiveness of early administration of tirofiban in patients treated with alteplase for acute ischemic stroke

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004630
Enrollment
Unknown
Registered
2014-05-04
Start date
2014-05-08
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

rt-PA group:rt-PA 0.9mg/kg
rt-PA combined with tirofiban:rt-PA 0.9mg/Kg combined with tirofiban 0.4ug/kg load i.v., 30', after then, 0.1ug/kg in 24 hours

Sponsors

Department of Neurology, Daping Hospital,the Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 years old and older; 2) sudden onset of acute ischemic stroke with symptom onset to treatment (OTT) <=4.5 hours; 3) admission NIHSS score between 4 to 18; 4) a large artery occlusion with the region of decreased CBV less than one third of the region showing a prolonged MTT on CTP.

Exclusion criteria

Exclusion criteria: 1.History of stroke in the past 3 mo with severe disability; 2.Previous intracranial hemorrhage,neoplasm,subarachnoid hemorrhage, or arterial venous malformation; 3.Hypertension at time of treatment,systolic BP>185mmHg or diastolic BP>110mmHg; 4.Presumed septic embolus; 5.Recent(within 30d) surgery; 6.Recent(within 30d)trauma; 7.Recent(within 90d)severe head trauma; 8.Rencent(within 30d)or active systemic hemorrhage; 9.Oral anticoagulant therapy with INR>1.7; 10.Administered with heparin within 48h and with a abnormal APTT; 11.Platelets< 100x109/L,glucose<2.7 mmol/L; 12.Pregnant; 13.Treated by endovascular therapy after failure of intravenous rt-PA; 14.Rejected by the patients or their family member.

Design outcomes

Primary

MeasureTime frame
NIHSS score;modified Rankin Score;

Countries

China

Contacts

Public ContactZhang Meng

Department of Neurology, Daping Hospital, the Third Military Medical University

zhangmeng861@gmail.com+86 13708332600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026